Cyfuse Biomedical K.K. (4892) AI Stock Analysis

0 Followers

Cyfuse Biomedical K.K.

(TSE/TYO:4892)

Select Model

Rating:37Underperform

Price Target:JPY 468.00▼(-10.86% Downside)

Action:downgraded

Date:11/07/26

Cyfuse Biomedical K.K. receives a bottom-tier score primarily driven by significant profitability challenges, ongoing cash burn, and a highly speculative valuation. While massive top-line revenue growth highlights potential market acceptance, the stock's severe technical downtrend and reliance on external financing overshadow these gains. Extreme oversold technical conditions may offer short-term relief, but long-term viability heavily depends on the company's ability to control costs and eventually pivot toward profitability.

Positive Factors

Revenue reboundThe sharp 2025 revenue recovery shows that the company can generate materially higher sales when product demand and commercialization improve. If this growth is sustained, greater scale could help absorb fixed costs, support investment in the platform, and improve future operating leverage.

Negative Factors

Persistent unprofitabilityExtremely negative operating and net margins indicate that the current revenue base is not yet sufficient to support the cost structure. Persistent losses reduce retained capital, make self-funded expansion difficult, and leave future earnings dependent on substantial improvement in scale, pricing, or operating efficiency.

Cyfuse Biomedical K.K. (4892) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 5.28B
Dividend Yield: ―
Average Volume (3M): 50.03K
Price to Earnings (P/E): -6.5
Beta (1Y): 0.46
Revenue Growth: 364.72%
EPS Growth: 18.43%
Country: Japan
Employees: 23
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Cyfuse Biomedical K.K. Business Overview & Revenue Model

Company Description

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic...

Cyfuse Biomedical K.K. Financial Statement Overview

Summary

Explosive revenue growth of over 250% highlights strong commercial traction, but overall financial health is severely dragged down by persistent net losses, negative operating margins, and ongoing cash burn requiring external financing.

Income Statement

28Negative

Balance Sheet

52Neutral

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	305.90M	231.00M	54.45M	61.11M	374.48M	708.25M
Gross Profit	145.27M	78.40M	1.56M	-378.00K	223.93M	568.20M
EBITDA	-743.38M	-792.68M	-860.12M	-659.31M	-370.81M	89.07M
Net Income	-795.91M	-763.84M	-872.24M	-589.21M	-473.96M	142.91M
Balance Sheet
Total Assets	3.93B	4.27B	3.52B	4.21B	4.82B	2.65B
Cash, Cash Equivalents and Short-Term Investments	3.39B	3.73B	3.05B	3.87B	4.44B	2.41B
Total Debt	1.23B	1.31B	852.80M	913.00M	857.79M	569.06M
Total Liabilities	1.30B	1.51B	975.60M	1.01B	1.05B	746.12M
Stockholders Equity	2.62B	2.76B	2.54B	3.20B	3.77B	1.90B
Cash Flow
Free Cash Flow	0	-581.93M	-768.16M	-581.77M	-631.87M	161.54M
Operating Cash Flow	0	-534.79M	-760.55M	-562.30M	-403.60M	161.54M
Investing Cash Flow	0	-397.56M	-8.64M	-19.47M	-430.67M	-50.58M
Financing Cash Flow	0	1.26B	-52.01M	18.24M	2.66B	229.21M

Cyfuse Biomedical K.K. Technical Analysis

Technical Analysis SentimentNegative

Last Price525.00

Price Trends

50DMA602.64Negative

100DMA570.50Negative

200DMA601.15Negative

Market Momentum

MACD-23.11Positive

RSI37.20Neutral

STOCH48.02Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4892, the sentiment is Negative. The current price of 525.00 is below the 20-day moving average (MA) of 560.15, below the 50-day MA of 602.64, and below the 200-day MA of 601.15, indicating a bearish trend. The MACD of -23.11 indicates Positive momentum. The RSI at 37.20 is Neutral, neither overbought nor oversold. The STOCH value of 48.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4892.

Cyfuse Biomedical K.K. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

JP:4892 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:7079	80Outperform	JPY 6.13B	0.92	―	3.75%	-8.78%	0.01%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JP:4539	47Neutral	JPY 5.31B	-11.60	―	3.27%	0.31%	-194.72%
JP:4582	39Underperform	JPY 5.45B	-0.57	―	―	-30.58%	6.93%
JP:4883	39Underperform	JPY 3.36B	-1.12	―	―	―	25.34%
JP:4597	38Underperform	JPY 6.82B	-7.21	-53.67%	―	109.82%	61.98%
JP:4892	37Underperform	JPY 5.50B	-6.45	―	―	364.72%	18.43%

* Healthcare Sector Average

Performance Comparison

JP:4892 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:4892	Cyfuse Biomedical K.K.	525.00	-56.00	-9.64%
JP:4597	Solasia Pharma KK	24.00	-8.00	-25.00%
JP:4539	Nippon Chemiphar Co., Ltd.	1528.00	46.21	3.12%
JP:4582	Symbio Pharmaceuticals Limited	52.00	-56.00	-51.85%
JP:4883	Modalis Therapeutics Corporation	27.00	-43.00	-61.43%
JP:7079	WDB coco Co., Ltd.	2535.00	38.31	1.53%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026

Cyfuse Biomedical K.K. AI Stock Analysis